A prospective, phase II trial of monotherapy with low-dose afatinib for patients with EGFR, mutation-positive, non-small cell lung cancer: Thoracic oncology research group 1632-Reference-Cited by-同舟云学术

A prospective, phase II trial of monotherapy with low-dose afatinib for patients with EGFR, mutation-positive, non-small cell lung cancer: Thoracic oncology research group 1632

Published:2021-11 Issue: Volume:161 Page:49-54
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Noro Rintaro,Igawa Satoshi,Bessho Akihiro,Hirose Takashi,Shimokawa Tsuneo,Nakashima Masanao,Minato Koichi,Seki Nobuhiko,Tokito Takaaki,Harada Toshiyuki,Sasada Shinji,Miyamoto Shingo,Tanaka Yosuke,Furuya Naoki,Kaburagi Takayuki,Hayashi Hideki,Iihara Hirotoshi,Okamoto Hiroaki,Kubota Kaoru

Funder

Boehringer Ingelheim Japan

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference22 articles.

1. Cancer statistics, 2020;Siegel;CA Cancer J Clin.,2020

2. Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS;Wu;SSO and TOS. Ann Oncol.,2019

3. Hirsh V. Turning. EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors. Ther Adv Med Oncol. 2018. 22. 10. 1758834017753338. doi: 10.1177/1758834017753338.

4. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer;Chou;Clin. Cancer Res.,2005

5. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence;Mitsudomi;J. Clin. Oncol.,2005

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High-cost treatments for advanced lung cancer in Japan (Lung Cancer Study Group of the Japan Clinical Oncology Group);Japanese Journal of Clinical Oncology;2024-08-19

2. Clinical phase II trial shows that combining osimertinib and afatinib resistance EGFR recurrent mutation in EGFR-mutant lung cancer;Southeast Asian Journal of Health Professional;2024-03-15

3. Real-World Treatment Outcomes and Safety of Afatinib in Advanced Squamous Cell Lung Cancer Progressed after Platinum-Based Doublet Chemotherapy and Immunotherapy (SPACE Study);Cancers;2023-11-24

4. A Case of Binocular Metastatic Choroidal Tumor Originating from Pulmonary Adenocarcinoma Successfully Treated with Molecular Target Therapy;Case Reports in Ophthalmology;2023-09-08

5. Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial;Clinical Lung Cancer;2023-09